Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BEONE MEDICINES LTD | $39.77B | $359.05 | $395.86 | 10.25% | Strong Buy | 7 | 128.29% | 1,035.81% | 3,646.89% | 1,973.01% | |||
| NVO | NOVO NORDISK A S | $219.81B | $49.23 | $57.40 | 16.60% | Buy | 5 | 89.37% | 95.81% | 371.88% | 132.92% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $3.44B | $45.39 | $52.00 | 14.56% | Strong Buy | 5 | 26.14% | 82.87% | 42.45% | 31.91% | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $486.97M | $8.65 | $24.00 | 177.46% | Strong Buy | 2 | 53.52% | 77.69% | 139.83% | 68.93% | |||
| CORT | CORCEPT THERAPEUTICS INC | $4.19B | $39.82 | $100.00 | 151.13% | Buy | 3 | 43.18% | 97.94% | 137.02% | 105.13% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $44.12B | $332.68 | $480.15 | 44.33% | Strong Buy | 21 | 32.82% | 106.30% | 419.69% | 66.69% | |||
| VCEL | VERICEL CORP | $1.89B | $37.41 | $45.00 | 20.29% | Strong Buy | 1 | 21.67% | 84.65% | 29.97% | 21.28% | |||
| ARGX | ARGENX SE | $51.60B | $845.35 | $1.03k | 21.66% | Strong Buy | 16 | 1,549.76% | 24.66% | 51.25% | 43.54% | |||
| GMAB | GENMAB A | $18.73B | $29.16 | $41.58 | 42.60% | Strong Buy | 6 | 15.19% | 167.60% | 33.47% | 15.20% | |||
| KRYS | KRYSTAL BIOTECH INC | $8.28B | $283.29 | $332.29 | 17.30% | Strong Buy | 7 | 34.97% | 30.23% | 23.47% | 21.46% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $3.74B | $189.94 | $243.50 | 28.20% | Strong Buy | 6 | 14.25% | 69.68% | 24.08% | 15.49% | |||
| TECH | BIO-TECHNE CORP | $9.28B | $59.33 | $73.63 | 24.09% | Strong Buy | 8 | 6.01% | 70.59% | 21.86% | 17.43% | |||
| ADMA | ADMA BIOLOGICS INC | $3.81B | $15.99 | N/A | N/A | N/A | N/A | 27.01% | 23.80% | 114.85% | 87.08% | |||
| MNKD | MANNKIND CORP | $1.67B | $5.44 | $10.08 | 85.35% | Strong Buy | 6 | 22.22% | 64.28% | -453.45% | 40.84% | |||
| ABEO | ABEONA THERAPEUTICS INC | $277.46M | $5.12 | $20.00 | 290.63% | Buy | 1 | 817.16% | 17.10% | 81.99% | 60.75% | |||
| HALO | HALOZYME THERAPEUTICS INC | $8.64B | $73.23 | $79.00 | 7.88% | Buy | 8 | 14.15% | 59.19% | 2,414.25% | 46.67% | |||
| RPRX | ROYALTY PHARMA PLC | $26.15B | $45.34 | $47.75 | 5.32% | Strong Buy | 4 | 15.54% | 56.16% | 40.16% | 19.88% | |||
| VCYT | VERACYTE INC | $2.89B | $36.61 | $46.33 | 26.56% | Buy | 6 | 13.14% | 71.30% | 12.18% | 11.20% | |||
| XOMA | XOMA ROYALTY CORP | $301.53M | $24.35 | $72.67 | 198.43% | Strong Buy | 3 | 41.73% | 37.69% | N/A | N/A | |||
| NAGE | NIAGEN BIOSCIENCE INC | $399.03M | $5.00 | $14.00 | 180.00% | Strong Buy | 1 | 23.38% | 31.11% | 72.56% | 52.26% | |||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $239.66M | $2.98 | $12.00 | 302.68% | Buy | 1 | 17.29% | 152.57% | 29.17% | 18.76% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.03B | $35.28 | $45.00 | 27.55% | Buy | 6 | 16.93% | 37.81% | 82.79% | 57.22% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.99B | $24.29 | $33.00 | 35.86% | Strong Buy | 1 | 9.07% | 20.13% | 57.36% | 50.19% | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.89B | $14.31 | $17.33 | 21.13% | Buy | 3 | 19.54% | 30.63% | 43.26% | 30.00% | |||
| APLS | APELLIS PHARMACEUTICALS INC | $2.81B | $22.20 | $34.54 | 55.58% | Buy | 13 | 7.44% | 32.27% | 49.90% | 18.91% | |||
| CRMD | CORMEDIX INC | $564.92M | $7.17 | $15.40 | 114.78% | Buy | 5 | 30.97% | 1.79% | 40.60% | 20.23% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $83.75B | $792.16 | $820.32 | 3.55% | Buy | 19 | 10.05% | 12.58% | 23.27% | 17.93% | |||
| UTHR | UNITED THERAPEUTICS CORP | $20.50B | $476.05 | $514.18 | 8.01% | Buy | 11 | 11.37% | 8.75% | 28.02% | 25.12% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.88B | $61.83 | $83.91 | 35.71% | Strong Buy | 11 | 9.05% | 35.77% | 19.41% | 15.44% | |||
| ACAD | ACADIA PHARMACEUTICALS INC | $3.93B | $23.20 | $32.18 | 38.72% | Buy | 11 | 12.14% | 5.48% | 45.02% | 31.03% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $119.47B | $470.31 | $531.53 | 13.02% | Buy | 17 | 10.74% | 17.59% | 39.80% | 28.97% | |||
| INVA | INNOVIVA INC | $1.77B | $23.66 | $32.25 | 36.31% | Buy | 4 | 10.65% | 12.32% | 25.83% | 18.25% | |||
| EXEL | EXELIXIS INC | $11.55B | $44.47 | $44.36 | -0.24% | Buy | 11 | 12.98% | 18.26% | 73.93% | 56.18% | |||
| MDXG | MIMEDX GROUP INC | $773.09M | $5.22 | $9.33 | 78.79% | Strong Buy | 3 | 14.15% | 10.46% | N/A | N/A | |||
| INCY | INCYTE CORP | $20.50B | $102.99 | $109.29 | 6.11% | Buy | 14 | 8.38% | 15.45% | 19.12% | 14.20% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.